全文获取类型
收费全文 | 32326篇 |
免费 | 2676篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 552篇 |
儿科学 | 1286篇 |
妇产科学 | 1121篇 |
基础医学 | 4428篇 |
口腔科学 | 882篇 |
临床医学 | 2804篇 |
内科学 | 7425篇 |
皮肤病学 | 768篇 |
神经病学 | 3322篇 |
特种医学 | 1000篇 |
外国民族医学 | 3篇 |
外科学 | 3979篇 |
综合类 | 543篇 |
一般理论 | 43篇 |
预防医学 | 2352篇 |
眼科学 | 677篇 |
药学 | 1810篇 |
中国医学 | 8篇 |
肿瘤学 | 2078篇 |
出版年
2021年 | 467篇 |
2020年 | 300篇 |
2019年 | 502篇 |
2018年 | 565篇 |
2017年 | 400篇 |
2016年 | 430篇 |
2015年 | 499篇 |
2014年 | 674篇 |
2013年 | 1043篇 |
2012年 | 1351篇 |
2011年 | 1409篇 |
2010年 | 849篇 |
2009年 | 721篇 |
2008年 | 1280篇 |
2007年 | 1379篇 |
2006年 | 1376篇 |
2005年 | 1283篇 |
2004年 | 1273篇 |
2003年 | 1160篇 |
2002年 | 1244篇 |
2001年 | 1104篇 |
2000年 | 1178篇 |
1999年 | 987篇 |
1998年 | 373篇 |
1997年 | 311篇 |
1996年 | 325篇 |
1995年 | 294篇 |
1994年 | 284篇 |
1993年 | 306篇 |
1992年 | 863篇 |
1991年 | 805篇 |
1990年 | 686篇 |
1989年 | 726篇 |
1988年 | 675篇 |
1987年 | 705篇 |
1986年 | 650篇 |
1985年 | 675篇 |
1984年 | 536篇 |
1983年 | 462篇 |
1982年 | 294篇 |
1980年 | 259篇 |
1979年 | 453篇 |
1978年 | 304篇 |
1977年 | 257篇 |
1976年 | 276篇 |
1975年 | 263篇 |
1974年 | 299篇 |
1973年 | 294篇 |
1972年 | 266篇 |
1971年 | 260篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Gafner Michal Borovich Adi Gimpel Ariel Peled Yoav Meshulam Moshe Krissi Haim 《Archives of gynecology and obstetrics》2020,301(5):1207-1212
Archives of Gynecology and Obstetrics - To characterize the population of women who underwent mid-trimester preterm premature rupture of membrane (PPROM) in a country where mid-trimester abortions... 相似文献
2.
3.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
4.
5.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
6.
Julia Thornton Snider Jesse Sussell Mahlet Gizaw Tebeka Alicia Gonzalez Joshua T. Cohen Peter Neumann 《Value in health》2019,22(3):332-339
Background
Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.Objective
We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).Study Design
Retrospective analysis of pharmaceutical sales data.Methods
From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).Results
Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.Conclusions
This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results. 相似文献7.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献8.
Journal of Neuro-Oncology - 相似文献
9.
We present the case of 7‐year‐old African American girl with loose anagen syndrome. Although this is a common cause of hair loss in Caucasian children, and there have been reports of cases occurring in dark‐skinned children of North African and Middle Eastern descent, to our knowledge there have been no cases reported in black children of sub‐Saharan African ancestry. We present this case to broaden the differential diagnosis of hair loss in African Americans. 相似文献
10.